Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial
DosisPHERE-01 was a multicentre, open-label phase 2 trial done at four health-care centers in France. Patients had unresectable locally advanced hepatocellular carcinoma with at least one measurable lesion 7cm or more in size. They were given yttrium-90-loaded glass microspheres.
